latest news releases from the newsroom
XsunX CEO Comments on Annual Report
ALISO VIEJO, Calif., Dec. 18, 2006 (PRIME NEWSWIRE) -- XsunX, Inc. (OTCBB:XSNX), developer of advanced manufacturing systems and cell structures for solar energy, submitted its annual report on December 14, 2006 to the Securities Exchange Commission for its fiscal year, which ended September 30, 2006.
OrderPro Logistics Completes AWA Acquisition; TransMex Division Expands Container Yard Business
TUCSON, Ariz., Dec. 18, 2006 (PRIME NEWSWIRE) -- OrderPro Logistics, Inc. (Pink Sheets:OPLO) today announced that it has completed its acquisition of a 45% interest in All Win Alliance, Inc., (AWA). Among its technology services, All Win Alliance provides on-site computer networking sales and services, website hosting and design, high speed internet access, and application hosting to B2B (Business to Business) customers nationwide. Separately, OrderPro announced that due to increased demand from existing customers, it is expanding its container yard operations at its Illinois facility, and exploring additional stockyard services.
D Mecatronics Inc.
D Mecatronics Inc. Receives Purchase Order of $350,000 and Partners With Future Industry Leaders
MISSISSAUGA, Ontario, Dec. 18, 2006 (PRIME NEWSWIRE) -- D Mecatronics Inc. (Pink Sheets:DMTN) is a recognized technology pioneer and market leader in the area of engineering, design and the manufacturing of automated solutions for the automotive industry and is rapidly becoming one of the world's leading providers of automated manufacturing solutions, which are used primarily by three of the top ten Tier 1 automotive part suppliers in the world. The Company also makes precision components and tooling using its own custom-built manufacturing systems, process knowledge and automation technology.
Micron Enviro Systems, Inc.
Micron Enviro Systems, Inc. Announces Property Evaluation Expected Shortly For Leases in World-Class Alberta Oil Sands
VANCOUVER, British Columbia, Dec. 18, 2006 (PRIME NEWSWIRE) -- Micron Enviro Systems, Inc. (Frankfurt:NDDA), (WKN:A0J3PY), (OTCBB:MENV), ("Micron") is expecting to have a preliminary report that will give an estimate of the potential amount of oil in ground covering all of the Oil Sands leases that Micron has interests in. The majority of the world's largest oil companies have operations in the Alberta Oil Sands, which is one of the single largest natural resource regions on earth.
Encysive Pharmaceuticals Inc.
Encysive Pharmaceuticals Announces Launch of Thelin in Germany
HOUSTON, Dec. 18, 2006 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (Nasdaq:ENCY) today announced that THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets are now commercially available in Germany for the treatment of pulmonary arterial hypertension (PAH). The Company received European Union marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist and the first once-daily oral treatment available for patients with PAH.
Hydro's Oil and Gas activities to Merge With Statoil
OSLO, Norway, Dec. 18, 2006 (PRIME NEWSWIRE) -- The Board of Directors of Hydro and Statoil have agreed to recommend to their shareholders a merger of Hydro's oil and gas activities with Statoil, creating the world's largest offshore operator with a strengthened platform for future growth. The new company will have a combined production of 1.9 million barrels per day in 2007 and proven oil and gas reserves of 6.3 billion barrels of oil equivalents. Hydro will continue as a leading, focused global aluminium company.
Actelion Announces Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
ALLSCHWIL, Switzerland, Dec. 17, 2006 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN), (Other OTC:ALIOF) announced today that initial results from the double-blind, placebo-controlled, multicenter study EARLY (Endothelin Antagonist Trial in miLdly Symptomatic PAH patients, NYHA modified functional class II) indicate that six months of treatment with the dual endothelin receptor antagonist bosentan (Tracleer(r)) showed a significant reduction in pulmonary vascular resistance, a strong trend towards improved exercise capacity and a significant delay in the time to clinical worsening.